Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension

Drugs and Aging

Volumn 12, Issue 3, 1998, Pages 225-241

  Adkins, Julie C ^a   Balfour, Julia A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETAXOLOL; BRIMONIDINE; DORZOLAMIDE; LATANOPROST; PILOCARPINE; TIMOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS HUMOR; BLEPHARITIS; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; EYE IRRITATION; HUMAN; HYPEREMIA; INTRAOCULAR DRUG ADMINISTRATION; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; META ANALYSIS; NONHUMAN; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; REVIEW; SYSTOLIC BLOOD PRESSURE; XEROSTOMIA;

ADRENERGIC ALPHA-AGONISTS; AGED; CLINICAL TRIALS; GLAUCOMA, OPEN-ANGLE; HUMANS; OCULAR HYPERTENSION; QUINOXALINES;

EID: 0031886692     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199812030-00005     Document Type: Review

References (63)

1. Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol 1996 Nov; 41 Suppl. I: S9-18
2. Chien DS, Homsy JJ, Gluchowski C, et al. Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN-190342, and clonidine in rabbit eyes. Curr Eye Res 1990 Nov; 9: 1051-9
3. Quigley HA. Open-angle glaucoma. N Engl J Med 1993 Apr: 328 (15): 1097-106
4. Dreyer EB. Preserving eyesight with foresight. Harvard Health Lett 1994 Oct; 19: 4-6
5. Sommer A. Intraocular pressure and glaucoma. Am J Ophthalmol 1989; 107 (2): 186-8
6. Klein BEK, Klein R, Sponsel WE, et al. Prevalence of glaucoma: the Beaver Dam Eye Study. Ophthalmology 1992; 99: 1499-504
7. 2-adrenergic receptors: structure, function and therapeutic implications. Reading: Harwood Academic Publishers. 1996; 179-87
8. 2-agonist for the characterisation of α-adrenoceptor subtypes. Eur J Pharmacol 1981; 72: 413-5
9. Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995 Dec; 113: 1514-7
10. Burke J, Kharlamb A, Shan T, et al. Adrenergic and imidazoline receptor-mediated responses to UK-14,304-18 (brimonidine) in rabbits and monkeys: a species difference. Ann N Y Acad Sci 1995 Jul 12; 763: 78-95
11. Matsuo T, Cynader MS, Localization of alpha-2 adrenergic receptors in the human eye. Ophthalmic Res 1992; 24: 213-9
12. 2-adrenergic agonists B-HT 920 and UK14304-18. Effects on aqueous humor dynamics in monkeys. Arch Ophthalmol 1991 Aug; 109: 1158-62
13. Gabelt BT, Robinson JC, Hubbard WC, et al. Apraclonidine and brimonidine effects on anterior ocular and cardiovascular physiology in normal and sympathectomized monkeys. Exp Eye Res 1994 Dec; 59: 633-44
14. 2-adrenergic agonists on uveoscleral outflow in rabbits [abstract]. Invest Ophthalmol Vis Sci 1991; 32 Suppl.: 867
15. Burke JA, Potter DE. Ocular effects of a relatively selective α2 agonist (UK-14, 304-18) in cats, rabbits and monkeys. Eye Res 1986; 5 (9): 665-76
16. R). timolol and betaxolol [abstract no. 3792-B393]. Invest Ophthalmol Vis Sci 1997; 38 Suppl.: S814
17. Nordlund JR, Pasquale LR, Robin AL, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. Arch Ophthalmol 1995 Jan; 113: 77-83
18. Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology 1997 Jan; 104: 131-6
19. Rosenthal AL, Walters T, Berg E, et al. A comparison of the safety and efficacy of brimonidine 0.2%, BID versus TID, in subjects with elevated intraocular pressure [abstract no. 5071-B681]. Invest Ophthalmol Vis Sci 1996 Feb 15; 37 (3): S1102
20. Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996 Nov; 41 Suppl. 1: 27-37
21. Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. Arch Ophthalmol 1997 Jul; 115: 847-52
22. Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. Surv Ophthalmol 1996 Nov; 41 Suppl. 1: S39-47
23. Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol 1996 Nov; 41 Suppl. I: S19-26
24. Bhandari A, Orgul S, Bacon D, et al. Effect of brimonidine on optic nerve blood flow in rabbits [abstract no. 3631-B232]. Invest Ophthalmol Vis Sci 1997; 38 Suppl.: S738
25. Lachkar Y, Migdal C, Dhanjil S, et al. The effect of brimonidine on ocular blood flow [abstract no. 3602-B203]. Invest Ophthalmol Vis Sci 1997; 38 Suppl.: S778
26. 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology 1993 Aug; 79 (2): 306-12
27. Reis DJ, Regnnathan S, Mceley MP. Imidazole receptors and clonidine-displacing substance in relationship to control of blood pressure, neuroprotection, and adrenomedullary secretion. Am J Hypertens 1992; 5: 51S-7S
28. Lynch DR, Dawson TM. Secondary mechanisms in neuronal trauma. Curr Opin Neurol 1994; 7: 510-6
29. 2-adrenoceptor agonists AGN 191103 and brimonidine [abstract no. 540-B452]. Invest Ophthalmol Vis Sci 1996 Feb 15; 37 (3): S144
30. Lai R, Hasson D, Chun T, et al. Neuroprotective effect of ocular hypotensive agent brimonidine. XIth Congress of the European Society of Ophthalmology; 1997 Jun 1-5; Budapest: 439-44
31. Wallicke PA. Basic and acidic fibroblast growth factors have trophic effect on neurons from multiple CNS regions. J Neurosci 1988 Jul; 8 (7): 2618-27
32. 2-adrenergic agonists xylazine and clonidine [abstract]. Soc Neurosci Abstr 1995; 21 (Pt 2) Suppl.: S1045
33. Chien D-S, Luo A, Tang-Liu D. Ocular melanin binding of brimonidine (AGN 190342) in vitro [abstract]. Pharm Res 1991 Oct; 8 Suppl.: S-260
34. Acheampong AA, Shackleton M, Tang-Liu DD-S. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Dispos 1995 Jul; 23: 708-12
35. Chien D-S, Dais M, Tang-Liu D. Ocular metabolism of brimonidine in albino rabbits [abstract]. Pharm Res 1992 Oct; 9 Suppl.: S-287
36. Acheampong A, Kelley E, Chen K, et al. Effect of ocular dose on the systemic absorption and disposition of brimonidine in humans [abstract]. Pharm Res 1994 Oct; 11 Suppl.: S350
37. Acheampong A, Tang-Liu DD-S. Measurement of brimonidine concentrations in human plasma by a highly sensitive gas chromatography/mass spectrometric assay. J Pharm Biomed Anal 1995 Jul; 13: 995-1002
38. Tang-Liu D, Daher M, Shackleton M, et al. Use of a sensitive GCMS assay to determine the pharmacokinetic parameters of brimonidine in the mouse, rat, monkey and human [abstract]. Pharm Res 1992 Oct; 9 Suppl.: S345
39. Salazar M, Shimada K, Patil PN. Iris pigmentation and atropine mydriasis. J Pharmacol Exp Ther 1976; 197 (1): 79-88
40. Salminen L, Imre G, Huupponen R. The effect of ocular pigmentation on intraocular pressure response to timolol. Acta Ophthalmol 1985; 63 Suppl. 173: 15-8
41. Acheampong AA, Chien D-S, Lam S, et al. Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase. Xenobiotica 1996 Oct; 26: 1035-55
42. 14C-brimonidine after intravenous and oral doses to rats and monkeys [abstract]. Pharm Res 1991 Oct; 8 Suppl.: S251
43. The Brimonidine-ALT Study Group. Effect of brimonidine 0.5% on intraocular pressure spikes following 360° argon laser trabeculoplasty. Ophthalmic Surg Laser 1995 Sep-Oct; 26 (5): 404-9
44. Barnebey HS, Robin AL, Zimmerman TJ, et al. The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty. Ophthalmology 1993 Jul; 100: 1083-8
45. David R, Spaeth GL, Clevenger CE, et al. Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty. Arch Ophthalmol 1993 Oct; 111: 1387-90
46. Gandolfi SA. The additive effect of brimonidine 0.2%, BID compared with pilocarpine 2.0%. TID, in patients on beta-blocker monotherapy [abstract]. Joint European Research Meeting in Ophthalmology and Vision (JERMOV); 1997 Oct 15-19; Montpellier
47. Nagasubramanian S, Hitchings RA, Demailly P, et al. Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study. Ophthalmology 1993 Sep; 100 (9): 1318-23
48. Stewart WC, Laibovitz R, Horwitz B, et al. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Arch Ophthalmol 1996 Aug; 114: 938-42
49. Butler PJ, Jones B. Incidence of characteristics of allergic reaction to apraclonidine 0.5% [abstract]. Invest Ophthalmol Vis Sci 1996; 37 Suppl. 3: S201
50. Butler P, Mannschreck M, Lin S, et al. Clinical experience with the long-term use of 1% apraclonidine. Arch Ophthalmol 1995 Mar; 113: 293-6
51. Gordon RN, Ritch R, Liebmann JM, et al. Alpha-agonist allergy: is there cross reactivity between apraclonidine and brimonidine? [abstract no. 2601-B291]. Invest Ophthalmol Vis Sci 1997; 38 Suppl.: S559
52. Allergan Inc. Alphagan®: brimonidine tartrate ophthalmic solution 0.2% prescribing information. Irvine, California, USA, 1997
53. Allergan Limited. Alphagan® (brimonidine tartrate ophthalmic solution) 0.2%. Summary of product characteristics. Bucking-hamshire. UK, March 1997
54. Migdal C, Gregory W, Hitchings R. Long-term functional outcome after laser surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology 1994; 101: 1651-7
55. Abel Jr RS, Abel AD. Ocular diseases. In: Speight TM, Holford NHG, editors. Avery's drug treatment. 4th ed. Auckland: Adis International Limited, 1997: 581-605
56. Brooks AMV, Gillies WE. Ocular β-blockers in glaucoma management: clinical pharmacological aspects. Drugs Aging 1992 May-Jun; 2: 208-21
57. Patel SS, Spencer CM. Latanoprost: a review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 1996 Nov; 9: 363-78
58. Serle JB. Pharmacological advances in the treatment of glaucoma. Drugs Aging 1994 Sep: 5: 156-70
59. Balfour JA, Wilde MI. Dorzolamide: a review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging 1997 May; 10: 384-403
60. Everitt DE, Avorn J. Systemic effects of medications used to treat glaucoma. Ann Intern Med 1990 Jan 15; 112: 120-5
61. Morrison JC. Side effects of α-adrenergic agonists. J Glaucoma 1995; 4 Suppl. 1: S36-8
62. Hurvitz LM, Kaufman PL, Robin AL, et al. New developments in the drug treatment of glaucoma. Drugs 1991 Apr; 41: 514-32
63. Hodapp E, Kolker AE, Kass MA, et al. The effcet of topical clonidine on intraocular pressure. Arch Ophthalmol 1981 Jul; 99: 1208-11